Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Earnings of $-0.11 Expected in Q1 for NxStage Medical, Inc. (NASDAQ:NXTM) - The Markets Daily |
 |
 |
|
Sell-side Wall Street analysts are anticipating NxStage Medical, Inc. (NASDAQ:NXTM) will post a current quarter earnings per share of $-0.11. This figure is based on the combined estimates of the analysts that cover the company. For the period ending on 2014-12-31 the company reported earnings per share of $-0.08. Based on the latest public information, the firm is slated to next report earnings on or around 2015-05-06. Analysts that cover the stock have a mean consensus price target of $21 for NxStage Medical, Inc. (NASDAQ:NXTM) .This one year figure is the mean estimate coming from the research analysts that recently released reports on stock. The latest update on price target was seen on 2015-04-15. An arithmetical average of the ratings given by analysts to develop a Consensus Analyst Rating for each company is known as the broker recommendation. These ratings fall on a scale between 1 and 5 where a 1 would be a Strong Buy and a 5 would constitute a Strong Sell. Of the 4 broker recommendations provided, NxStage Medical, Inc. has a 2 rating. Out of these analysts, one contributor sees the stock price hitting $24 within the year while the most bearish target sees the stock at $15. If we look forward at the long term growth estimates for the company, research analysts are expecting current year earnings per share to be $-0.37. The highest broker full year earnings per share estimate is $ $-0.33 while the lowest estimate sits at $-0.37. Company Profile NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market. |
